HYFT

MindWalk Holdings Corp. is a biotechnology company listed in the healthcare sector with a market capitalization of $105.52 million. The company operates on a relatively small scale, employing 81 individuals and generating revenue of $26.65 million in its latest trailing twelve months (TTM). While these numbers do not place MindWalk among the largest companies in its industry, it is notable for achieving a revenue growth rate of 53.9% year-over-year. MindWalk Holdings Corp.'s financial health is a concern, with significant net losses reported over the TTM period. The company's operating margin and profit margin are deeply negative at -67.3% and -111.9%, respectively, indicating substantial operational challenges. Furthermore, returns on equity (ROE) and return on assets (ROA) have been severely negative at -118.2% and -15.1%, respectively. However, the company's balance sheet is relatively stable, with cash reserves of $16.51 million and a modest debt level of $3.63 million. In terms of valuation, MindWalk Holdings Corp.'s price to book ratio stands at 8.09 and its price to sales ratio is 3.96, indicating that investors are paying approximately 8 times the company's book value or 4 times its annual revenue per share. The company's forward P/E ratio and EBITDA multiple (EV/EBITDA) are not available. The dividend yield and payout ratio are also not applicable as MindWalk does not currently pay a dividend.